

Smart Matrix Limited

Appointment of Non-Executive Director

01 December 2018, Smart Matrix Limited ('SML' or 'the Company'), which is developing healing without a skin graft, is very pleased to announce today that Bill Allan, who is currently senior advisor to the board, has been appointed as non-executive Director with immediate effect.

Bill, who has served as senior advisor to the board since November 2017, has been appointed to provide continuity and expertise to the Board, bringing a wealth of experience from the wound care and medical devices industry and an international perspective.

During the past ten years, Bill has led and transitioned three small medical device companies to sale. During the preceding 15 years, he worked for Smith & Nephew in sales, marketing, business development and general management in Africa, North America and Europe. Bill is a qualified dental surgeon and holds business qualifications from the University of Cape Town (MBA), Ashridge Management College and INSEAD Business School (AMP).

Further changes to the board announced today include the stepping down of Swen Lorenz after almost three years' service as a non-executive director.

Francis Gugen, Executive Chairman, said: "We are sad to see Swen go after the tremendous contribution he has made during a critical phase of the Company's development culminating in this year's move from bench to bed. I am extremely pleased to be able to welcome to the Board Bill Allan as a non-executive director who brings a lifetime's experience in healthcare, including in particular in wound care, medical devices and as a seasoned entrepreneur himself."

Bill Allan, Non-executive Director, added: "I am excited about the prospects of Smart Matrix®, with its potential to close wounds without a skin graft. I am looking forward to bringing my experience to bear to see this product realise its full potential for the benefit of the Company but also the large number of patients who suffer skin grafts every year."

For further information, please contact:

SmartMatrix Ltd

Francis Gugen, Executive Chairman

+44 (7785) 326-291

Notes:**The Board will now comprise*****Francis Gugen, Executive Chairman***

Has a proven track record in establishing, building from scratch and chairing successful businesses including as CH4 Limited, realising investors €224m or 7.4 times their investment in just over 3 years, Chrysaor, now one of the largest North Sea producers, acquiring over half Shell's UK production for some \$3.8bn, IGas, now one of the largest onshore UK oil and gas players and a big data businesses in the financial services sector.

CEO experience, where at Amerada Hess was initially part of a team that took this small player, with a few dozen staff, to become the third largest producer in the UK; with Francis becoming CEO Europe.

Dr Lilian Hook, Chief Scientific Officer

Oversees Smart Matrix® product research and development and joined SML team part-time in 2014 and permanently in August 2017.

20 years' experience in biomedical research, in both industry and academia. In previous roles, has focused primarily on the application of stem cells and regenerative medicine.

PhD in Development Biology from the University of Edinburgh. Degree in Natural Sciences from Cambridge.

Jeremy Curnock Cook, Non-Executive Director

Funds management expertise, most recently creating new funds of A\$100m, and A\$50m, targeting the healthcare sector. Responsible for more than 150 private company investments over the past 30 years, together with the creation and management of specialised healthcare investment funds valued at more than \$1b.

Bill Allan, Non-Executive Director

Bill Allan is an experienced medical device and wound care executive, currently CEO of SurgaColl Technologies and having previously held numerous leadership positions including CEO at Vascular Flow Technologies, VP and General Manager at Stryker Orthobiologics, various senior positions over many years at Smith & Nephew.

About Smart Matrix Limited

Smart Matrix Limited ('SML') was spun out of the Restoration of Appearance and Function Trust ("RAFT"), a medical research charity based at Mount Vernon hospital, Middlesex, UK, in late 2011.

SML is focused on the commercialisation of products from a proprietary platform technology developed originally by RAFT scientists based on a matrix manufactured from fibrinogen and thrombin, natural products of the healing process, and alginate, a product derived from seaweed and widely used in wound care products.

The first product developed from this platform is Smart Matrix®, a scaffold designed to help the body close surgical wounds and regenerate lost skin, for healing without a skin graft; a potential game changer. Smart Matrix® works by encouraging the growth of skin cells and new blood vessels, critical to healthy healing.

To date SML has been supported by investments of over £9.1 million, from a small group of highly experienced investors, including seven either current or past CEOs or chairs of FTSE 100 companies.

For further information see: www.smartmatrix.co.uk